Sawai Announces Listing of Five Generic Drugs with 11 Strengths

Osaka, Japan – June 16, 2022 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Kenzo Sawai) today announced the listing of five generic drugs with 11 strengths in the NHI (National Health Insurance) drug price list. Sawai's product line now includes 329 compounds with 809 strengths.

The list of new products:

1. Febuxostat Tablets, OD Tablets

Generic name:	Febuxostat	Strengths:	Tablets: 10mg, 20mg, 40mg
			OD Tablets: 10mg, 20mg
Brand products:	Feburic [®] Tablets 10mg, 20mg, 40mg		

2. Aripiprazole Tablets, Oral Solution

ſ	Generic name:	Aripiprazole	Strengths:	Tablets: 1mg
				Oral Solution: 1mg
I	Brand products:	ABILIFY [®] tablets 1mg, ABILIFY [®] oral solution 0.1%		

3. Dasatinib Tablets

Generic name:	Dasatinib Hydrate	Strengths:	Tablets: 20mg, 50mg
Brand products:	SPRYCEL [®] Tablets 20mg, 50mg		

4. Azacitidine for Injection

Generic name:	Azacitidine	Strengths:	Injection: 100mg
Brand products:	Vidaza [®] for Injection 100mg		

5. Teriparatide Injection

Generic name:	Teriparatide Acetate	Strengths:	Injection: 56.5µ
Brand products:	Teribone [®] Injection 56.5µg		

The products announced in this press release are not approved by the Food & Drug Administration for sale and distribution in the United States.

♦ Contact Information
♦
Public Relations Office, Sawai Pharmaceutical Co., Ltd.
E-mail : <u>koho@sawai.co.jp</u>